Therapeutic options for PD1 refractory skin cancer

In this podcast, we explore the latest advancements in the treatment of PD-1 refractory melanoma. This week, we are joined by Allison Betof Warner (Stanford Cancer Center, Stanford, CA) and Omid Hamid (The Angeles Clinic and Research Institute, Los Angeles, CA) and Inderjit Mehmi (The Angeles Clinic and Research Institute, Los Angeles, CA).

We will hear about the clinical definitions and significance of PD-1 resistance, including insights from SITC on primary and secondary resistance. The discussion will also highlight the implications for clinical trial design and strategies to overcome resistance in melanoma therapy. Updates on emerging treatment options, including the combination of immunotherapies, promising data from trials involving tumor-infiltrating lymphocytes (TIL) and oncolytic viruses, and recent FDA approvals that are shaping new treatment paradigms, are also discussed. Additionally, future directions in melanoma research, such as engineered T cells and other cellular therapies, and their potential to improve patient outcomes.

For more updates on melanoma and skin cancer research, be sure to visit our dedicated Skin Cancer Channel.

Subscribe to our podcasts on Apple Podcasts, Podbean, and Spotify, and join the conversation via X @VJOncology. Stay tuned for more insights at VJOncology.com.